<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749407</url>
  </required_header>
  <id_info>
    <org_study_id>HZCH-2021-02</org_study_id>
    <nct_id>NCT04749407</nct_id>
  </id_info>
  <brief_title>Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer</brief_title>
  <official_title>Dynamic Biomarkers of Immune Microenvironment for Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to dynamically monitor the expression profile status of peripheral blood&#xD;
      mononuclear cells (PBMC) and the changes in circulating tumor DNA (ctDNA) levels in patients&#xD;
      with stage III locally advanced unresectable non-small-cell lung cancer(NSCLC) after&#xD;
      concurrent chemoradiotherapy or sequential chemoradiotherapy, and to explore biomarkers&#xD;
      related to the immune microenvironment and the optimal time point for immunotherapy after&#xD;
      chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers associated with immune efficacy</measure>
    <time_frame>up to 2 years</time_frame>
    <description>According to the biomarker detection before and after chemoradiotherapy to identify biomarkers related to the immune microenvironment, including the expression levels of NK cells, T cells, B cells and other immune cells reflected by PBMC, as well as the expression levels of ctDNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal time for immunotherapy</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Changes in the expression levels of ctDNA and PBMC immune cells before and after chemoradiotherapy to find the optimal time point for immunotherapy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>biomarker detection</intervention_name>
    <description>PBMC and ctDNA analysis</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Stage III locally advanced unresectable Non-small cell lung cancer (NSCLC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed, written and dated informed consent prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Male or female aged over 18 years and under 70 years&#xD;
&#xD;
          3. Patients must have histologically- or cytologically-documented NSCLC who present with&#xD;
             locally advanced, unresectable (Stage III) disease (according to Version 7 of the&#xD;
             International Association for the Study of Lung Cancer Staging Manual in Thoracic&#xD;
             Oncology [IASLC Staging Manual in Thoracic Oncology]), and clinical evaluation is&#xD;
             suitable for concurrent chemoradiotherapy or sequential chemoradiotherapy&#xD;
&#xD;
          4. With measurable lesions (according to RECIST 1.1 criteria, long diameter of tumor&#xD;
             lesions is 10mm, short diameter of lymph node lesions is 15mm).&#xD;
&#xD;
          5. World Health Organization (WHO) Performance Status of 0~2&#xD;
&#xD;
          6. Life expectancy ≥6 months&#xD;
&#xD;
          7. Adequate organ and marrow function as defined below:&#xD;
&#xD;
             Absolute neutrophil count &gt;1.5 x 109/L (1500 per mm3) Platelets &gt;90 x 109/L (90,000&#xD;
             per mm3) Haemoglobin ≥9.0 g/dL (5.59 mmol/L) Serum creatinine CL &gt;50 mL/min by the&#xD;
             Cockcroft-Gault formula Serum bilirubin ≤1.5 x upper limit of normal (ULN) Total&#xD;
             bilirubin (TBIL) ≤ 1.5 x upper limit of normal (ULN) In patients with no liver&#xD;
             metastasis: AST and ALT ≤2.5 x ULN In patients with liver metastasis: AST or ALT ≤5 x&#xD;
             ULN Urinary protein &lt;2+; If the urine protein is ≥2+, the 24-hour urine protein&#xD;
             quantification must show the protein to be ≤1g&#xD;
&#xD;
          8. International standardized ratio of normal coagulation function, no active bleeding&#xD;
             and thrombosis disease International standardized ratio INR≤1.5×ULN Partial&#xD;
             thromboplastin time APTT≤1.5×ULN Prothrombin time Pt ≤1.5 UlN&#xD;
&#xD;
          9. For women of non-surgical sterilization or reproductive age, use of a medically&#xD;
             approved contraceptive method (such as an intrauterine device, birth control pills, or&#xD;
             condoms) during the study treatment period and within 3 months after the study&#xD;
             treatment period; Women of reproductive age who are not surgically sterilized must be&#xD;
             negative for serum or urine HCG within 7 days prior to study enrolment; And must be&#xD;
             non-lactation; Male patients who are not surgically sterilized or of reproductive age&#xD;
             need to agree to use a medically approved method of contraception with their spouse&#xD;
             for the duration of the study treatment period and for three months after the end of&#xD;
             the study treatment period&#xD;
&#xD;
         10. Patients volunteered to participate in this study with good compliance and cooperated&#xD;
             with multiple blood sample collection and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients should not enter the study if any of the following exclusion criteria are&#xD;
        fulfilled:&#xD;
&#xD;
          1. With other uncontrollable malignancies&#xD;
&#xD;
          2. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody&#xD;
&#xD;
          3. With any active autoimmune disease or a history of primary immunodeficiency (such as&#xD;
             the following, but not limited to: autoimmune hepatitis interstitial pneumonia,&#xD;
             uveitis, enteritis, hepatitis, the pituitary gland inflammation, vasculitis,&#xD;
             nephritis, thyroid function, thyroid function is reduced, always had thyroid surgery&#xD;
             must be incorporated into; Subjects with vitiligo or asthma in complete remission&#xD;
             during childhood were included without any intervention as adults)&#xD;
&#xD;
          4. Patients are taking immunosuppressive or systemic or absorbable topical hormone&#xD;
             therapy for immunosuppressive purposes (dose &gt;10mg/day prednisone or other hormone)&#xD;
             and continued to be used within 2 weeks before enrolment&#xD;
&#xD;
          5. Patients with congenital or acquired immune deficiency, such as HIV infection, or&#xD;
             active hepatitis (transaminase does not meet the reference, hepatitis B: HBV&#xD;
             DNA≥104/ml; hepatitis C: HCV RNA≥103/ml); Chronic hepatitis B virus carriers, HBV&#xD;
             DNA&lt;2000 IU/ml(&lt;104 copies /ml) and must receive antiviral therapy during the trial to&#xD;
             be included in the study&#xD;
&#xD;
          6. Patients with ≥2 grade pneumonitis from prior chemoradiation therapy&#xD;
&#xD;
          7. History of psychotropic substance abuse, alcohol abuse or drug abuse&#xD;
&#xD;
          8. Female patients who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control&#xD;
&#xD;
          9. Any condition that, in the opinion of the investigator, would interfere with study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shirong Zhang, Ph.D</last_name>
    <phone>057156007664</phone>
    <email>shirley4444@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shirong Zhang, Dr.</last_name>
      <phone>057156007650</phone>
      <email>shirley4444@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III locally advanced unresectable non-small-cell lung cancer</keyword>
  <keyword>circulating tumor DNA</keyword>
  <keyword>peripheral blood mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

